Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Peter Atadja
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Anatomy
Phenomena
Living Beings
Physiology
Procedures
Sign-in to see full Profile
Network (preview)
18
Bhalla, Kapil
12
Fiskus, Warren
9
Bali, Purva
7
Rao, Rekha
6
Remiszewski, Stacy
6
Yang, Yonghua
5
Qian, David
5
Pili, Roberto
5
Guo, Fei
4
Moscinski, Lynn
4
Trogani, Nancy
4
Wu, Jie
3
Wei, Yongfeng
3
Weisberg, Ellen
3
Salumbides, Brenda
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Peter Atadja (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Fiskus Warren; Wang Yongchao; Sreekumar Arun; Buckley Kathleen M; Shi Huidong; Jillella Anand; Ustun Celalettin; Rao Rekha; Fernandez Pravina; Chen Jianguang; Balusu Ramesh; Koul Sanjay; Atadja Peter; Marquez Victor E; Bhalla Kapil N
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Blood 2009;114(13):2733-43.
-
2009: Prystowsky Michael B; Adomako Alfred; Smith Richard V; Kawachi Nicole; McKimpson Wendy; Atadja Peter; Chen Quan; Schlecht Nicolas F; Parish Joanna L; Childs Geoffrey; Belbin Thomas J
The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines.
The Journal of pathology 2009;218(4):467-77.
-
2009: Atadja Peter
Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.
Cancer letters 2009;280(2):233-41.
-
2009: Ellis Leigh; Bots Michael; Lindemann Ralph K; Bolden Jessica E; Newbold Andrea; Cluse Leonie A; Scott Clare L; Strasser Andreas; Atadja Peter; Lowe Scott W; Johnstone Ricky W
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.
Blood 2009;114(2):380-93.
-
2009: Kim In Ah; No Mina; Lee Jang Mi; Shin Jin Hee; Oh Jee Sun; Choi Eun Jung; Kim Il Han; Atadja Peter; Bernhard Eric J
Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2009;92(1):125-32.
-
2009: Ellis Leigh; Atadja Peter W; Johnstone Ricky W
Epigenetics in cancer: targeting chromatin modifications.
Molecular cancer therapeutics 2009;8(6):1409-20.
-
2009: Floris Giuseppe; Debiec-Rychter Maria; Sciot Raf; Stefan Cristiana; Fieuws Steffen; Machiels Kathleen; Atadja Peter; Wozniak Agnieszka; Faa Gavino; Schöffski Patrick
High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4066-76.
-
2009: Fiskus Warren; Buckley Kate; Rao Rekha; Mandawat Aditya; Yang Yonghua; Joshi Rajeshree; Wang Yongchao; Balusu Ramesh; Chen Jianguang; Koul Sanjay; Joshi Atul; Upadhyay Sunil; Atadja Peter; Bhalla Kapil N
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells.
Cancer biology & therapy 2009;8(10):939-50.
-
2009: Chen Jianguang; Fiskus Warren; Eaton Kelly; Fernandez Pravina; Wang Yongchao; Rao Rekha; Lee Pearl; Joshi Rajeshree; Yang Yonghua; Kolhe Ravindra; Balusu Ramesh; Chappa Prasanthi; Natarajan Kavita; Jillella Anand; Atadja Peter; Bhalla Kapil N
Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.
Blood 2009;113(17):4038-48.
-
2009: Symanowski James; Vogelzang Nicholas; Zawel Leigh; Atadja Peter; Pass Harvey; Sharma Sunil
A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(2):149-60.
-
2008: de Bono Johann S; Kristeleit Rebecca; Tolcher Anthony; Fong Peter; Pacey Simon; Karavasilis Vasilios; Mita Monica; Shaw Heather; Workman Paul; Kaye Stan; Rowinsky Eric K; Aherne Wynne; Atadja Peter; Scott Jeffrey W; Patnaik Amita
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6663-73.
-
2008: Rosato Roberto R; Almenara Jorge A; Maggio Sonia C; Coe Stefanie; Atadja Peter; Dent Paul; Grant Steven
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.
Molecular cancer therapeutics 2008;7(10):3285-97.
-
2008: Fiskus Warren; Rao Rekha; Fernandez Pravina; Herger Bryan; Yang Yonghua; Chen Jianguang; Kolhe Ravindra; Mandawat Aditya; Wang Yongchao; Joshi Rajeshree; Eaton Kelly; Lee Pearl; Atadja Peter; Peiper Stephen; Bhalla Kapil
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
Blood 2008;112(7):2896-905.
-
2008: Rao Rekha; Fiskus Warren; Yang Yonghua; Lee Pearl; Joshi Rajeshree; Fernandez Pravina; Mandawat Aditya; Atadja Peter; Bradner James E; Bhalla Kapil
HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
Blood 2008;112(5):1886-93.
-
2008: Ellis Leigh; Pan Yan; Smyth Gordon K; George Daniel J; McCormack Chris; Williams-Truax Roxanne; Mita Monica; Beck Joachim; Burris Howard; Ryan Gail; Atadja Peter; Butterfoss Dale; Dugan Margaret; Culver Kenneth; Johnstone Ricky W; Prince H Miles
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4500-10.
-
2008: Yang Yonghua; Rao Rehka; Shen Jie; Tang Yun; Fiskus Warren; Nechtman John; Atadja Peter; Bhalla Kapil
Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion.
Cancer research 2008;68(12):4833-42.
-
2008: Verheul Henk M W; Salumbides Brenda; Van Erp Karen; Hammers Hans; Qian David Z; Sanni Tolib; Atadja Peter; Pili Roberto
Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3589-97.
-
2008: Yu Chunrong; Friday Bret B; Yang Lin; Atadja Peter; Wigle Dennis; Sarkaria Jann; Adjei Alex A
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Neuro-oncology 2008;10(3):309-19.
-
2008: Zhou Qun; Agoston Agoston T; Atadja Peter; Nelson William G; Davidson Nancy E
Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells.
Molecular cancer research : MCR 2008;6(5):873-83.
-
2008: De Bruyne Elke; Bos Tomas Jan; Asosingh Kewal; Vande Broek Isabelle; Menu Eline; Van Valckenborgh Els; Atadja Peter; Coiteux Valérie; Leleu Xavier; Thielemans Kris; Van Camp Ben; Vanderkerken Karin; Van Riet Ivan
Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(10):2918-26.
-
2008: Scuto Anna; Kirschbaum Mark; Kowolik Claudia; Kretzner Leo; Juhasz Agnes; Atadja Peter; Pullarkat Vinod; Bhatia Ravi; Forman Stephen; Yen Yun; Jove Richard
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.
Blood 2008;111(10):5093-100.
-
2008: Chung Yuen-Li; Troy Helen; Kristeleit Rebecca; Aherne Wynne; Jackson L Elizabeth; Atadja Peter; Griffiths John R; Judson Ian R; Workman Paul; Leach Martin O; Beloueche-Babari Mounia
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.
Neoplasia (New York, N.Y.) 2008;10(4):303-13.
-
2007: Edwards Arthur; Li Jiannong; Atadja Peter; Bhalla Kapil; Haura Eric B
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.
Molecular cancer therapeutics 2007;6(9):2515-24.
-
2007: Fiskus Warren; Ren Yuan; Mohapatra Alex; Bali Purva; Mandawat Aditya; Rao Rekha; Herger Bryan; Yang Yonghua; Atadja Peter; Wu Jie; Bhalla Kapil
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4882-90.
-
2007: Yu Chunrong; Friday Bret B; Lai Jin-Ping; McCollum Andrea; Atadja Peter; Roberts Lewis R; Adjei Alex A
Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1140-8.
-
2007: Kato Yukihiko; Salumbides Brenda C; Wang Xiao-Fei; Qian David Z; Williams Simon; Wei Yongfeng; Sanni Tolib B; Atadja Peter; Pili Roberto
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
Molecular cancer therapeutics 2007;6(1):70-81.
-
2007: Zhou Qun; Atadja Peter; Davidson Nancy E
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation.
Cancer biology & therapy 2007;6(1):64-9.
-
2006: Fiskus Warren; Pranpat Michael; Balasis Maria; Herger Bryan; Rao Rekha; Chinnaiyan Arul; Atadja Peter; Bhalla Kapil
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Molecular cancer therapeutics 2006;5(12):3096-104.
-
2006: Catley Laurence; Weisberg Ellen; Kiziltepe Tanyel; Tai Yu-Tzu; Hideshima Teru; Neri Paola; Tassone Pierfrancesco; Atadja Peter; Chauhan Dharminder; Munshi Nikhil C; Anderson Kenneth C
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Blood 2006;108(10):3441-9.
-
2006: Qian David Z; Kachhap Sushant K; Collis Spencer J; Verheul Henk M W; Carducci Michael A; Atadja Peter; Pili Roberto
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.
Cancer research 2006;66(17):8814-21.
-
2006: Leyton Julius; Alao John P; Da Costa Marco; Stavropoulou Alexandra V; Latigo John R; Perumal Meg; Pillai Radhakrishna; He Qimin; Atadja Peter; Lam Eric W-F; Workman Paul; Vigushin David M; Aboagye Eric O
In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Cancer research 2006;66(15):7621-9.
-
2006: Fiskus Warren; Pranpat Michael; Bali Purva; Balasis Maria; Kumaraswamy Sandhya; Boyapalle Sandhya; Rocha Kathy; Wu Jie; Giles Francis; Manley Paul W; Atadja Peter; Bhalla Kapil
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.
Blood 2006;108(2):645-52.
-
2006: Maiso Patricia; Carvajal-Vergara Xonia; Ocio Enrique M; López-Pérez Ricardo; Mateo Gema; Gutiérrez Norma; Atadja Peter; Pandiella Atanasio; San Miguel Jesús F
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Cancer research 2006;66(11):5781-9.
-
2006: Qian David Z; Kato Yukihiko; Shabbeer Shabana; Wei Yongfeng; Verheul Hendrik M W; Salumbides Brenda; Sanni Tolib; Atadja Peter; Pili Roberto
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(2):634-42.
-
2006: Rosato Roberto R; Maggio Sonia C; Almenara Jorge A; Payne Shawn G; Atadja Peter; Spiegel Sarah; Dent Paul; Grant Steven
The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide.
Molecular pharmacology 2006;69(1):216-25.
-
2005: Rosato Roberto R; Almenara Jorge A; Maggio Sonia C; Atadja Peter; Craig Ruth; Vrana Julie; Dent Paul; Grant Steven
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Molecular cancer therapeutics 2005;4(11):1772-85.
-
2005: Chen Liwei; Meng Songshu; Wang Hai; Bali Purva; Bai Wenlong; Li Benyi; Atadja Peter; Bhalla Kapil N; Wu Jie
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.
Molecular cancer therapeutics 2005;4(9):1311-9.
-
2005: Bali Purva; Pranpat Michael; Bradner James; Balasis Maria; Fiskus Warren; Guo Fei; Rocha Kathy; Kumaraswamy Sandhya; Boyapalle Sandhya; Atadja Peter; Seto Edward; Bhalla Kapil
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
The Journal of biological chemistry 2005;280(29):26729-34.
-
2005: George Prince; Bali Purva; Annavarapu Srinivas; Scuto Anna; Fiskus Warren; Guo Fei; Sigua Celia; Sondarva Gautam; Moscinski Lynn; Atadja Peter; Bhalla Kapil
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Blood 2005;105(4):1768-76.
-
2004: Weisberg E; Catley L; Kujawa J; Atadja P; Remiszewski S; Fuerst P; Cavazza C; Anderson K; Griffin J D
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(12):1951-63.
-
2004: Qian David Z; Wang Xiaofei; Kachhap Sushant K; Kato Yukihiko; Wei Yongfeng; Zhang Lu; Atadja Peter; Pili Roberto
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Cancer research 2004;64(18):6626-34.
-
2004: Bali Purva; George Prince; Cohen Pamela; Tao Jianguo; Guo Fei; Sigua Celia; Vishvanath Anasuya; Scuto Anna; Annavarapu Srinivas; Fiskus Warren; Moscinski Lynn; Atadja Peter; Bhalla Kapil
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):4991-7.
-
2004: Brieger Angela; Boehrer Simone; Schaaf Simone; Nowak Daniel; Ruthardt Martin; Kim Soo-Zin; Atadja Peter; Hoelzer Dieter; Mitrou Paris S; Weidmann Eckhart; Chow Kai Uwe
In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
Biochemical pharmacology 2004;68(1):85-93.
-
2004: Romanski Annette; Bacic Biserka; Bug Gesine; Pfeifer Heike; Gul Hilal; Remiszewski Stacy; Hoelzer Dieter; Atadja Peter; Ruthardt Martin; Ottmann Oliver G
Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.
Haematologica 2004;89(4):419-26.
-
2004: Guo Fei; Sigua Celia; Tao Jianguo; Bali Purva; George Prince; Li Yunqing; Wittmann Sylvie; Moscinski Lynn; Atadja Peter; Bhalla Kapil
Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
Cancer research 2004;64(7):2580-9.
-
2004: Atadja Peter; Gao Lin; Kwon Paul; Trogani Nancy; Walker Heather; Hsu Meier; Yeleswarapu Lakshmi; Chandramouli Nagarajan; Perez Larry; Versace Richard; Wu Arthur; Sambucetti Lidia; Lassota Peter; Cohen Dalia; Bair Kenneth; Wood Alexander; Remiszewski Stacy
Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.
Cancer research 2004;64(2):689-95.
-
2004: Atadja Peter; Hsu Meier; Kwon Paul; Trogani Nancy; Bhalla Kapil; Remiszewski Stacy
Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824.
Novartis Foundation symposium 2004;259():249-66; discussion 266-8, 285-8.
-
2003: Fuino Lianne; Bali Purva; Wittmann Sylvie; Donapaty Sreenivas; Guo Fei; Yamaguchi Hirohito; Wang Hong-Gang; Atadja Peter; Bhalla Kapil
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
Molecular cancer therapeutics 2003;2(10):971-84.
-
2003: Catley Laurence; Weisberg Ellen; Tai Yu-Tzu; Atadja Peter; Remiszewski Stacy; Hideshima Teru; Mitsiades Nicholas; Shringarpure Reshma; LeBlanc Richard; Chauhan Dharminder; Munshi Nikhil C; Schlossman Robert; Richardson Paul; Griffin James; Anderson Kenneth C
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
Blood 2003;102(7):2615-22.
-
2003: Nimmanapalli Ramadevi; Fuino Lianne; Bali Purva; Gasparetto Maura; Glozak Michele; Tao Jianguo; Moscinski Lynn; Smith Clayton; Wu Jie; Jove Richard; Atadja Peter; Bhalla Kapil
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Cancer research 2003;63(16):5126-35.
-
2002: Gao Lin; Cueto Maria A; Asselbergs Fred; Atadja Peter
Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.
The Journal of biological chemistry 2002;277(28):25748-55.
-
2002: Remiszewski Stacy W; Sambucetti Lidia C; Atadja Peter; Bair Kenneth W; Cornell Wendy D; Green Michael A; Howell Kobporn Lulu; Jung Manfred; Kwon Paul; Trogani Nancy; Walker Heather
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
Journal of medicinal chemistry 2002;45(4):753-7.
-
2002: Fischer Denise D; Cai Richard; Bhatia Umesh; Asselbergs Fred A M; Song Chuanzheng; Terry Robert; Trogani Nancy; Widmer Roland; Atadja Peter; Cohen Dalia
Isolation and characterization of a novel class II histone deacetylase, HDAC10.
The Journal of biological chemistry 2002;277(8):6656-66.
-
2002: Atadja Peter; Yan-Neale Yan; Towbin Harry; Buxton Frank; Cohen Dalia
Gene expression profiling of epothilone A-resistant cells.
Novartis Foundation symposium 2002;243():119-32; discussion 132-6, 180-5.
Sign-in to see more
